Pfizer struck a deal with the US to sell medications at a discounted price on the TrumpRx platform and to invest in onshore manufacturing facilities in return for 3 years of tariff relief. This led to a huge rally in the sector: AstraZeneca, Pfizer, Merck & Co, Roche, Eli Lilly, Glaxo, and Sanofi were all up over 10% in equities.
• AstraZeneca announced plans to have a dual listing in New York. Not particularly credit relevant but may have contributed to the equity rally.
• Novartis gained FDA approval for Remibrutinib to treat chronic urticaria (hives). The drug may have peak annual sales of anywhere from $1.75bn to $3bn according to analyst estimates. This helps replace Entresto loss.
• Danaher became the latest Healthcare borrower to tap the CHF market. The company follows Zimmer Biomet, Roche, Thermo Fisher and Bayer in issuing a multi-tranche deal for CHF 1.25bn.

Find more articles and bullets on these widgets:
See below for a selection of analyst comments on the August inflation round:

Swedish August flash inflation is due tomorrow at 0700BST/0800CET and will be key in determining whether the Riksbank can cut rates as early as the September 23 decision. Markets currently price the September decision as a coin toss between a 25bp cut and hold.